These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7402308)

  • 1. The role of D-1 and D-2 receptors.
    Schachter M; Bédard P; Debono AG; Jenner P; Marsden CD; Price P; Parkes JD; Keenan J; Smith B; Rosenthaler J; Horowski R; Dorow R
    Nature; 1980 Jul; 286(5769):157-9. PubMed ID: 7402308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dopaminergic receptors in the regulation of growth hormone secretion.
    Müller EE; Liuzzi A; Cocchi D; Panerai AE; Oppizzi G; Lacatelli V; Mantegazza P; Silvestrini F; Chiodini PG
    Adv Biochem Psychopharmacol; 1977; 16():127-38. PubMed ID: 142419
    [No Abstract]   [Full Text] [Related]  

  • 4. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
    Parkes JD; Debono AG; Marsden CD
    J Neurol Neurosurg Psychiatry; 1976 Nov; 39(11):1101-8. PubMed ID: 1036999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine and dopamine receptor stimulation.
    Debono AG; Marsden CD; Asselman P; Parkes JD
    Br J Clin Pharmacol; 1976 Dec; 3(6):977-82. PubMed ID: 22216518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
    Carey RM; Thorner MO; Ortt EM
    J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dopaminergic blockade on the secretion of growth hormone and prolactin in man.
    Masala A; Delitala G; Alagna S; Devilla L; Rovasio PP; Lotti G
    Metabolism; 1978 Aug; 27(8):921-6. PubMed ID: 672613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of blood levels of prolactin and somatotropin as indices of pharmacological effects on the central nervous system].
    Barreca T; Gallamini A; Murialdo G; Nizzo MC; Polleri A
    Clin Ter; 1978 Jul; 86(2):147-59. PubMed ID: 743856
    [No Abstract]   [Full Text] [Related]  

  • 14. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic Modulation of renin activity and aldosterone and prolactin secretion in the spontaneously hypertensive rat.
    Sowers JR; Sollars EG; Tuck ML; Asp ND
    Proc Soc Exp Biol Med; 1980 Sep; 164(4):598-603. PubMed ID: 6997889
    [No Abstract]   [Full Text] [Related]  

  • 16. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
    Koller WC; Herbster G
    Neurology; 1987 Apr; 37(4):723-7. PubMed ID: 3561789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of dopamine receptors (type 2) lowers human intraocular pressure.
    Mekki QA; Turner P
    Br J Ophthalmol; 1985 Dec; 69(12):909-10. PubMed ID: 4084483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic drugs inhibit prolactin release from rat anterior pituitary cells in culture by a mechanism not involving the dopamine receptor.
    West B; Dannies PS
    Endocrinology; 1979 Apr; 104(4):877-80. PubMed ID: 436760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
    Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
    Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.